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ABSTRACT
THE EFFECT OF 830NM LIGHT ON INFLAMMATION IN RETINITIS
PIGMENTOSA
by
Krystal M. Bach
The University of Wisconsin-Milwaukee, 2015
Under the Supervision of Dr. Janis T. Eells
Purpose: Retinitis Pigmentosa (RP) is an inherited retinal degenerative disease
and the most common cause of blindness in developed countries, affecting
approximately 1 in 4,000 people. RP is characterized by photoreceptor cell death
and recent studies suggest that chronic inflammation may play a key role in the
pathogenesis of RP. Currently, there are no known treatments or preventive
measures to delay or halt the loss of photoreceptor cells. Photobiomodulation
(PBM) by light in the far-red or near-infrared (NIR) range of the light spectrum
has been documented to help promote cell survival and reduce inflammation in
several disease states. Recent studies in the P23H rat model of RP have shown
that 830nm PBM attenuated photoreceptor cell loss and protected retinal
function. The current studies test the hypothesis that 830nm PBM produces an
anti-inflammatory environment in the retina to protect against photoreceptor cell
loss.
Methods: Studies were conducted in compliance with the ARVO Statement for
the Use of Animals in Ophthalmic and Visual Research. P23H rats were
irradiated with 830nm light (180 s; 25 mW/cm2; 4.5 J/cm2) using a light-emitting
diode array once per day from postnatal day (p)17 to 27. Sham treated controls
ii

were restrained for 180 seconds, but not exposed to the 830nm light. Retinas
were harvested at p30. Retinal concentrations of ten inflammatory mediators
were determined using a multiplex bead-based immunosorbent assay.
Results: Our findings indicate that retinal concentrations of four of the ten
inflammatory mediators, CINC-3, IL-10, VEGF, and TIMP-1 differed between the
dystrophic P23H rats and the non-dystrophic SD rats. Statistically significant
differences were only observed in TIMP-1, with concentrations in the P23H
retinas that were twice that measured in the SD retinas. 830nm PBM produced
no changes in retinal concentrations of the 10 inflammatory mediators measured
compared to the sham treatment.
Conclusion: Our data indicated that the inflammatory environment of the
dystrophic P23H rat and the non-dystrophic SD rat differ. The data also shows
that 830nm PBM had no measurable effect on these inflammatory mediators at
p30. Further studies with greater numbers of animals are needed to investigate
the time course of inflammation in this rodent model of RP and to define potential
effects of PBM.
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CHAPTER 1: INTRODUCTION
I. Background
Retinitis Pigmentosa
Etiology
Retinitis Pigmentosa (RP) is a group of inherited retinal degenerative
diseases that cause the progressive loss of vision due to the death of
photoreceptor cells. RP is the most common cause of blindness in developed
countries and affects approximately 1 in 4,000 people, worldwide (1-5). RP is an
extremely heterogenic disease with multiple modes of inheritance. It is estimated
that 30-40% of all RP cases are caused by autosomal dominant mutations, 5060% are caused by autosomal recessive mutations, 5-15% are X-linked, and a
small portion exhibit complex polygenic inheritance and non-Mendelian
inheritance (1, 5-7). In addition, RP has been associated with over 30 different
syndromes. These syndromic conditions account for 20-30% of all RP cases (1,
8, 9). The most common RP syndromes are Usher syndrome (10-20% of RP
cases) and Bardet-Biedl syndrome (5-6% of RP cases) (1, 8, 10).
Over 45 gene loci have been shown to be involved in RP, with genetic
mutations affecting a wide variety of metabolic pathways. Mutations have been
characterized in the phototransduction cascade, from protein trafficking to
metabolic functions, and in cellular structures both inside and outside the ocular
tissues (1, 8, 9). Although most mutations only account for a very small
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percentage of RP cases, there are few exceptions. The most commonly affected
genes are RPGR, USH2A, and RHO. Together, mutations in these three genes
represent 30% of all RP cases (1, 9). Mutations in the RHO gene, which encodes
for the G-protein coupled photon receptor rhodopsin, are the most common.
These mutations are present in 25% of autosomal dominant cases of RP, and 810% of all cases of RP (1, 11-14).
RHO is a highly conserved 7,000 base pair gene among vertebrates (11,
15). It codes for a 348 amino acid light sensitive protein, also known as an opsin.
Opsin is a seven segment transmembrane protein located in the discs of the
outer segments of photoreceptor cells. The seven transmembrane segments
form a pocket with a lysine residue in the middle. This residue binds the
chromophore 11-cis-retinal, which is derived from vitamin A (11). It is this
chromophore and opsin together that form the visual pigment rhodopsin, which
absorbs light in the eye initiating the visual cycle (15). Therefore, it is no surprise
that defects in RHO have the potential to severely impair vision. Over 40
mutations and deletions known to cause RP have been found in RHO (11, 16).
These mutations impair normal protein folding and transportation, rhodopsin’s
incorporation into the photoreceptor’s outer segments, the binding of 11-cisretinal, and the G-protein coupling and activation of rhodopsin (11, 15).
Of the mutations affecting the rhodopsin molecule, the P23H mutation is
the most commonly reported, causing 12% of all autosomal dominant RP cases
(12, 17). The P23H mutation is caused by a single base-pair substitution,
changing a cytosine to an adenine in the 23rd codon. Normally, this codon
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produces the amino acid proline, but the mutation results in a histidine being
placed at that location instead (17). The exact function of the proline at codon 23
is unknown; however, this particular codon is very highly conserved, as it is
present in the same location in other opsins and rhodopsin homologs of
vertebrates and invertebrates alike (17). It has been demonstrated that the P23H
mutant rhodopsin is misfolded due to the substitution. This misfolding results in
the inability of the 11-cis-retinal chromophore to properly incorporate into the
rhodopsin molecule. The mutant rhodopsin is also less photosensitive, and is
rapidly degraded due to its instability in the cells (12). Approximately 10% of the
mutant rhodopsin produced is successfully transported to the outer segments of
the photoreceptors (18). This greatly impacts the rod photoreceptor cells’ ability
to function, as 90% of all the proteins found in the outer segment are rhodopsin
(15). The misfolded proteins that do successfully integrate into the outer segment
membranes cause the photoreceptor cell to be structurally disorganized, and it
has been proposed that this disorganization is a potential cause of the
photoreceptor cell degeneration (18). In addition, the misfolded protein tends to
aggregate in the endoplasmic reticulum (ER), where it is produced (12, 19, 20).
The accumulation of misfolded proteins generates stress in the ER and activates
the unfolded protein response (UPR). The UPR attempts to either repair or
eliminate misfolded proteins by upregulating the production of the ER stress
transducers inositol-requiring protein-1 (IRE-1), protein kinase RNA-like ER
kinase (PERK), and activating transcription factor 6 (ATF6). The molecular
chaperone binding immunoglobulin protein (BiP), which is found in the lumen of
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the ER, senses the misfolded rhodopsin proteins and activates the stress
transducers. Once activated, IRE-1, PERK, and ATF6 promote the degradation
of the misfolded proteins by either ER-associated protein degradation (ERAD) or
autophagy (21). However, as the mutant proteins are constantly being
reproduced, it is suggested that the UPR is overwhelmed as the cell cannot
adapt to the constant stress or attenuate the UPR due to the excessive
degradation occurring. This results in an increased production of reactive oxygen
species (ROS), which triggers a cascade of pro-apoptotic signals, leading to the
death of photoreceptor cells (19, 21, 22).

Clinical Manifestations
Although RP is actually an umbrella term for many similar yet
heterogeneous retinopathies, RP is generally characterized by the degeneration
rod photoreceptors followed by a secondary deterioration of the cone
photoreceptors (1, 8). This step-wise degeneration of the photoreceptors makes
the typical progression of the disease definable in three stages known as early,
mid, and end stage RP (8).
The early stage commonly occurs during the early or adolescent years (1,
8). At this point, the rods are just beginning to degrade and the only symptom is a
mild night blindness or difficulties adjusting to dark conditions. This is due to a
ring scotoma, or blind spot, that begins to form in the mid-periphery of the visual
field (1, 8, 11, 23). Symptoms at this stage can be easily missed as artificial
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lighting may help conceal the defect, and the patient may not notice any
difficulties during their day-to-day activities. Even if the patient is examined, tests
are usually performed in light conditions that do not reflect the dark conditions
needed to diagnose the loss of vision (1, 8). An examination of the retina is also
of limited use at this stage, as the fundus has a relatively normal appearance
with potentially only a slight attenuation of the retinal arterioles (8, 11, 23).
During the mid-stage of the disease, the ring scotoma has progressed into
the far-peripheral field of vision and is noticeable in day light conditions, as well
as, at night (1, 17, 23, 24). The night blindness is pronounced and affects routine
activities (8). The patient may also begin to experience photophobia in diffuse
light conditions (8). In addition, at this stage the cone photoreceptors are
beginning to degenerate, and color vision may be affected. In particular, there is
a decreased detection of pale colors such as blue and yellow (1, 8, 11). The
retina begins to have an abnormal appearance. Bone-spicules, which are areas
of exposed retinal epithelial (RPE) cells due to the death of the covering
photoreceptor cells (25), are found in the periphery of the fundus. There is also
an obvious narrowing of the retinal arterioles and a slight paling of the optic disc
(8, 11, 23). At this stage of the disease, the development of cataracts is common,
occurring in nearly 50% of RP patients (24, 26). With the constriction of the
patient’s remaining vision into a central field, the development of a cataract can
effectively blind the patient if not removed. Throughout the mid-stage the
progression of the disease should be carefully monitored, as on average patients
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lose 4.6% of their remaining vision per year (23). Once a patient’s visual field
reaches 10 degrees or less, they are considered legally blind (24).
The end stage occurs when the patient’s vision has decayed into a small
central field known as tunnel vision (1, 8, 11, 23, 24). The restriction of the
patient’s vision severely impairs their ability to function. Often, by the age of 40
patients are legally blind, and can lose their remaining central vision by the age
of 60 (1, 11). Although only photoreceptor cells degenerate during the early and
mid-stages of RP, during the end stage, all retinal cells begin to degenerate (1),
resulting in the atrophy of the retina. Furthermore, bone-spicules are found
throughout both the macular and peripheral areas of the fundus, the optic disc
has waxy appearance, and the retinal vessels are extremely attenuated (8, 11,
17).
RP can be clearly diagnosed and assessed during the latter half of the
disease’s progression by examining the symptoms; however, attempting to
assess RP during its early stages by identifying symptoms can be misleading. As
mentioned before, patients often do not notice symptoms during the early stage
and it is not until cone degeneration is already involved that patients may report
symptoms. It has been observed that while 180 degrees is the normal field of
vision, patients with only 130 degrees will not even notice the reduction in vision
while performing daily tasks (27). A patient can lose up to 90% of their cones in
the fovea before a reduction in vision is even perceived (28). Therefore, clinical
assessments of RP need to measure the patient’s visual function directly to
accurately diagnose early cases of RP.
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Electroretinograms (ERGs) are one of the best methods for assessing the
development of RP. This non-invasive procedure stimulates the photoreceptors
with flashes of light. The electrical response is recorded using an electrode either
placed on a contact lens or the eyelid. The response of the rod and cone
photoreceptors can be measured together or separately depending on the stimuli
used. A rod dominant response can be achieved by dark-adapting the patient’s
eyes for 20 minutes, then exposing them to a single flash of dim blue light. A
flickering 30Hz white light can be used in light-adapted condition to measure the
response of only the cones, as stimulus greater than 20Hz are too fast for the
rods to follow. To measure the overall response of both photoreceptors, a single
bright white flash of light can be used. This produces an “a-wave,” which
represents the initial hyperpolarization of the photoreceptors, and a “b-wave,”
which is the subsequent depolarization of the bipolar cells. The amplitudes of
each wave form and the time between peaks can be used to determine the
functionality of the photoreceptor cells (29, 30). Patients with RP have decreased
ERG a-wave and b-wave amplitudes and delayed response times, with the
severity depending on the inheritance pattern of the disease and the stage of
progression (29, 30). ERGs can be used as effective tools to help diagnose RP,
as abnormal responses can be detected years to decades before any symptoms
even begin to develop (31).
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Current Treatments
There is a large variability between patients with RP due to the genetic
heterogeneity and individual environmental factors. This has made the
development of effective treatments difficult. Currently, the only treatable forms
of RP are those caused by the three metabolic syndromic disorders (32).
Bassen-Kornzweig disease, also known as abetalipoproteinemia, is an
autosomal recessive disorder that results in the malabsorption of fats and the fatsoluble vitamins A, D, E, and K. Among its other symptoms, the vitamin A
deficiency causes retinal degeneration (33, 34). The loss of retinal function in
these cases of RP can be reversed with high doses of vitamin A and E
supplements if treated before permanent retinal damage occurs (33, 34). The
second treatable syndromic RP condition is Refsum’s disease, also known as
phytanic acid oxidase deficiency. Refsum’s disease is a lipid metabolism disorder
resulting from a deficiency of phytanic acid hydroxylase. This deficiency causes
an accumulation of the fatty acid phytanic acid in serum and tissues, including
RPE cells, leading to their degeneration. By maintaining a low phytol and low
phytanic acid diet, the development of RP can be avoided (35, 36). The last
treatable syndromic RP condition is familial isolated vitamin E deficiency, or αtocopherol transport protein deficiency, which is caused by mutation in the αtocopherol transfer protein gene ttpA (37). This ttpA mutation prevents the proper
absorption of vitamin E, resulting in neurodegeneration. High doses of vitamin E
supplements are sufficient to counter the deficiency and prevent RP (37).
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With the exception of these three syndromic conditions, there has been
limited success in developing effective therapies for RP. Gene therapies attempt
to correct the defective biochemical pathways, but the method used depends on
the specific mutation and inheritance type. Autosomal Recessive mutations are
often caused by a mutation which results in the loss of a function, and gene
transfer therapies designed for these mutation aim to restore the wild type
function. For example, RPE-/- dogs are a model of Leber congenital amaurosis
(LCA), an inherited retinal degenerative disease similar to RP that occurs within
the first few months or years of life. Animals affected with this disease lack an
isomerase needed in the retinoid cycling process to change all-trans-retinal back
into 11-cis-retinal. This deficiency results in the accumulation of all-trans-retinal
and the degeneration of RPE and photoreceptor cells (38, 39). In a study
performed by Acland et al., three four-month old RPE-/- dogs were injected in the
subretinal space with a recombinant adeno-associated virus (rAAV) vector
carrying the wild type RPE65. The results of ERGs, pupillary response times, and
behavioral tests all showed significantly improved visual function 95 days after
the injection (38). The experiment was repeated with a larger sample size of 17
dogs and demonstrated that the visual improvement was maintained for at least
three years and retinal degeneration was reduced (39). These two studies were
used as a proof of concept to initiate clinical trials of the gene therapy; however,
when the patients who had received the rAAV-RPG65 therapy were examined, it
was found that although visual function was improved for up to three years, the
degeneration of photoreceptors was unabated (40). To further examine the

10
discrepancies between the canine models and clinical trials, Cideciyan et al.
compared the natural progression of the disease in humans and various animal
models. The RPE65-/- dogs had a slower rate of disease progression, with a
dysfunctional only phase for 5-8 years before degeneration started, while
humans did not have this period and dysfunction and degeneration happened
simultaneously. When the dogs were treated at an older age when the
dysfunction and degeneration state matched the human disease state at the time
of treatment, the gene therapy was unable to slow the rate of degeneration (40).
A different type of gene therapy is needed for cases of RP caused by
autosomal dominant mutation, which normally results in the gain of an abnormal
function or product. Gene silencing therapies attempt to inhibit or remove the
abnormal gene product. RNA interference (RNAi) is one method currently being
tested. A study performed by Li Jang et al. used a mouse model of autosomal
dominate RP to study the long term effects of this technique. Subretinal injections
of a rAAV vector carrying the RNAi cassette delayed the photoreceptor
degeneration and increased visual function for up to 11 months in the mice (41).
While these results are promising, clinical trials of RNAi gene silencing are still in
progress and it is unknown if they will face the same problems as the gene
transfer treatments. Even if the obstacles of treatment timing with gene therapy
are overcome, a unique therapy is required for each mutation, and with only 60%
of the causal mutations identified for RP (1), there is still a great deal of research
to be done before gene therapy can be an effective treatment option for patients.
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Several dietary supplements are used as therapies to slow the rate of
retinal degeneration, despite limited clinical evidence. A randomized clinical trial
involving 61 RP patients with various inheritance patters demonstrated that
15,000 IU/day of retinyl palmitate as a vitamin A supplement caused a modest,
but significantly lower rate of decline in cone ERG amplitude over the course of
four to six years. However, the rate of visual field and acuity loss did not differ
from the controls (42). Because of this study, vitamin A supplements are
recommended to patients with RP, even though the efficacy of the treatment is
still questioned. In addition, there are potential negative side effects to the high
doses of vitamin A that patients need to be aware of, such as liver toxicity,
osteoporosis in postmenopausal women, and birth defects with pregnant women
(43-45). Docosahexaenoic acid (DHA) is another dietary supplement has been
used. DHA is an omega-3 fatty acid found in cell membranes, with particularly
high concentrations in photoreceptor cells (46-48). Several studies have
examined its effect on the visual function of RP patients, both alone and with
other dietary supplements. The first study observed 44 males with X-linked RP
who were given either 400mg of DHA per day or a placebo for four years. The
patient’s ERGs, visual fields, acuity, dark adaptation, and fundus appearance
was assessed annually along with the concentration of DHA found in the
patient’s red blood cells (RBC). No significant differences were observed
between the DHA group and the placebo despite significantly elevated levels of
RBC DHA concentrations (46). A second study examining the effects of DHA
increased the dose and combined it with vitamin A supplements in 208 patients
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with various forms of RP. The patients were given either 1,200 mg of DHA with
15,000 IU of retinyl palmitate per day, a control plus 15,000 IU/day of retinyl
palmitate, or a control plus a placebo for four years. Again, no significant
differences were observed in the annual ERGs or visual field and acuity of the
patients (47). However, after further examination of the study’s subjects, it was
noticed that the patients who were not taking any vitamin A supplements prior to
the start of the study had slower rates of vision loss for the first two years when
given DHA and retinyl palmitate. It was also noted that while the results were not
significant, the patients who had the highest concentration of DHA in their RBCs,
had the slowest rates of visual decline. Interestingly, in the control groups that
were given only retinyl palmitate or a placebo, it was found that those who
consumed 1.4mg/day or more of omega-3 fatty acids in their diet had 40-50%
slower rates of visual field loss compared to those who did not (48).
Light protection is another approach to attenuate the rate of retinal
degeneration. Animal models provide evidence that bright light exposure
increases the degeneration rate of photoreceptors in RP (49), and that either light
constraint or constant darkness can slow the rate of degeneration (50). However,
case studies examining the effect of light constraint in human eyes has not
shown any protective benefits. In two different case studies, a RP patient had
one eye normally exposed to light and the other either experimentally covered for
six hours a day or closed due to a childhood physical trauma (51, 52). In both
cases, when the retinas of the exposed and protected eyes were compared, no
differences were observed in the state of disease. However, these cases do not
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take into account any potential systemic effects of the light exposure; therefore,
more studies are needed to determine the full effect of light protection. Still, it is
recommended to patients that they wear amber colored sunglasses with side
protection to block ultraviolet and visible light up to 572nm to help reduce
photophobia (8).
For the RP patients who have already lost their vision, there are few
treatment options that attempt to restore the retinal tissue and visual function.
Retinal transplants attempt to insert layers of various retinal and RPE cells into
the subretinal space of a degenerated adult retina. However, while these
transplanted donor cells seem to survive in the host, the new cells often do not
function properly. The transplanted cells show no evidence of developing
functional synaptic pathways with the host’s neurons, and the transplanted cells
tend to form rosettes instead of organizing into the appropriate retinal layer.
Similar difficulties have been observed with transplanted stem cells, as these
cells do not seem to be able to integrate into the host’s retina and develop into
photoreceptor cells (53). Maclaren et al. proposed that these issues may be
overcome if committed photoreceptor precursor cells were used instead of stem
cells or developed cells. In 2006, Maclaren et al. demonstrated with a murine
model that by harvesting the donor cells from a developing retina during the peak
of rod photoreceptor genesis and injecting them into the subretinal space of an
adult retina, the transplanted cells were able to integrate properly into the outer
nuclear layer of the retina and develop into mature rod photoreceptors with the
correct morphology. Furthermore, when transplanted in this manner into three
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different murine models of inherited retinal degeneration, these cells were able to
integrate into the degenerated retina, form functional synaptic connections, and
improve visual function (53). Retinal prosthetics are another treatment that show
promise for patients completely blinded by RP. Several studies testing 16electrode epiretinal implants in the eyes of patients blinded by RP have shown
the device is able to allow the patient to sense light, directions of motion, and
differentiate an object’s spatial orientation (54, 55). It is hoped that by increasing
the electrode numbers and density in the implants, the patients will experience
greater visual function with better resolution.
There is still much research to be done before a truly effective treatment
option is available for patients with RP. Although much is known about the
majority of the genetic mutations and the phenotypic manifestations, relatively
little is known about the mechanisms of the disease. The heterogenetic nature of
RP makes it unlikely that one treatment will be effective for all RP patients;
increasing our understanding of the biochemical and cellular changes that drive
the progression of RP is key to the development of any effective treatments.

Ocular Immunity
Immune Regulation
The eye is considered to be an immune privileged organ, meaning it has a
unique tolerance to the presence of antigens, severely limiting any potential
inflammatory response. The specialized cells found in the ocular tissue are highly
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sensitive to damage, and like most neurons, are postmitotic and have limited
regenerative capabilities (56). Therefore, the collateral damage caused by a
robust inflammatory response may do more harm than good. The eye limits its
immune reactivity using several different mechanisms. One mechanism it uses is
known as anterior chamber associated immune deviation (ACAID). ACAID is a
specialized method for developing systemic tolerance to retinal antigens. The
local antigen presenting cells (APC) detect antigens found within the anterior
chamber of the eye and carry them to the thymus and spleen to create a central
tolerance to the retinal antigen. Antigen-specific regulatory T cells are also
produced to impair reactive cell responses (57). The blood retinal barrier (BRB)
is another mechanism the eye uses to limit its immune reactivity. The endothelial
cells of the retinal microvasculature are non-fenestrated and form tight junctions
to prevent the passage of any large molecules or cells from the choroid to the
retina. Likewise, the tight junctions between the RPE cells work as part of the
BRB to maintain the homeostasis by controlling the transport of nutrients, waste,
and ions between the photoreceptors and the choroid (58, 59). The eye also
lacks lymphatic drainage pathways to limit the movement of leukocytes and
antigens (60). In addition to physically limiting the access of immune cells, many
ocular cells have properties designed to suppress the immune response. For
example, many ocular cells either lack or have a low expression of the major
histocompatibility complex (MHC) class 1α protein to inhibit the activation of T
cells. Many ocular cells also constitutively express the Fas ligand, which will
trigger apoptosis in any lymphoid cells expressing the Fas receptor. Furthermore,
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many immunomodulating proteins are expressed in the eye, such as
complement-inhibiting proteins and anti-inflammatory cytokines like the
membrane attack complex inhibitory protein (MAC-IP/CD59), and transforming
growth factor β (TGF-β) (56, 60, 61).
Due to the immune separation of the eye from the rest of the body, the
eye contains its own immunocompetent cells. The two predominant cells with
critical immune functions are the retinal pigment epitheial (RPE) cells and
microglial cells. The RPE is a single layer of cells between the photoreceptors
and choroid, it performs many critical functions aside from being part of the BRB.
The RPE acts as an attachment site, binding the rest of the retina to the choroid.
It phagocytizes the shed discs from the photoreceptor cells, and it is involved in
the retinoid cycling process needed to maintain visual function. Furthermore, the
melanin pigment found within the RPE absorbs the excess scattered light in the
eye to prevent damage to the retina (59). Moreover, the RPE plays a significant
role in modulating both the innate and adaptive immune responses in the retina.
RPE cells are capable of expressing both MHC class I and II proteins, allowing
them to function as APCs in the retina. Additionally, they express a variety of
factors including Fc-γ receptors, toll-like receptors (TLR), complement
components, growth factors, and a variety of cytokines and chemokines (62-67).
In particular, it has been demonstrated that RPE cell will express interleukin (IL)6, IL-8, and monocyte chemoattractant protein (MCP)-1 as pro-inflammatory
cytokines, and interferon (IFN)-β, IL-11, and TGF-β as anti-inflammatory factors
(66, 68).
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Microglial cells are the primary immunocompetent cell in the retina. They
enter the retina early in embryonic development and work to maintain
homeostasis as well as functioning at the resident macrophage in the eye (69).
Microglia exist in two states, resting and activated. While the microglial cells are
in the resting state they have a ramified morphology and are found primarily
within the inner retina among the ganglion and bipolar cells (69-71). The
microglia remain dormant in this state until they are activated by infectious
agents, cellular debris, lipopolysaccharides, or reactive oxygen species (ROS)
(69, 72, 73). Once activated, the microglia enlarge to take on an amoeboid
shape with enhanced abilities to proliferate, migrate, and phagocytize (69, 74).
The microglia also release multiple cytokines and chemokines, which include
MCP-1, IL-1β, IL-10, IFN-γ, macrophage inflammatory protein (MIP)-1α, and
tumor necrosis factor (TNF)-α. The activated microglial cells will also produce
neurotoxic factors including hydrogen peroxide and superoxide anion (75, 76). If
the activating stimulus is readily removed, the microglia will return to their resting
state; however, if the stimulus cannot be easily removed the microglia will adhere
to the surface of the nearby neurons and begin to continuously produce the
aforementioned factors, eventually causing the death of the neurons. The cellular
debris created from the dying neurons along with this constant production of
constituents activates and recruits additional microglia to the site causing
neuroinflammation (69, 75). The excessive production of cytotoxins from the
prolonged activation of microglial cells has been linked to neurodegeneration in
many diseases including experimental herpes encephalitis, West Nile Virus
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encephalitis, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral
sclerosis (77-81). Moreover, in the retina, the activation and infiltration of
microglial cells has been associated with the retinal degeneration observed in
light induced retinal injury and multiple forms of inherited retinal degeneration,
including RP (82-84).

Inflammation
The term “Retinitis Pigmentosa” was first used by the Dutch
ophthalmologist Dr. Franciscus Donders in 1857 to describe an ocular disorder
that presented with night blindness and developed characteristic black pigment
deposits on the retina. As the word retinitis is defined as “inflammation of the
retina,” it was originally believed that inflammation was a key factor in the
pathogenesis of the disease (85). For decades, studies have suggested that an
immune response may be involved in RP. In 1962, serum samples from six of ten
RP patients showed elevated levels of IgM antibodies in circulation (86). Again in
1973, a similar study found significantly increased concentrations of IgM in 52 RP
patients compared to 40 non-diseased patients (87). Moreover, a study
performed in 1980 by Brinkman et al. demonstrated that patients with RP had an
immunological response to retinal antigens while non-diseased patients did not.
When Brinkman et al. exposed the RP patients’ blood samples to human retinal
antigens or bovine rod outer segments, leukocytes migration, complement
fixation, and lymphocyte activation was observed (88). Additionally, in 1988,
macrophages, B cells, and various subsets of T cells were found in the vitreous
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fluid of three biopsy samples and eight postmortem samples from RP patients. In
each of the samples, two-thirds of the immune cells were found to be reactive,
whereas the immune cells in the vitreous fluid from non-diseased eyes, which
contained only a few macrophages, were mostly non-reactive (89). However, due
to the heterogeneity of the disease, there were also reports that found no
significant indication of inflammation. Because of these discrepancies, as the
genetic mutations behind RP were discovered, it was generally accepted that the
genetic defects were the primary cause of RP and the term “retinitis” was a
misnomer (85).
Nevertheless, recent studies indicate that inflammation may play a key
role in the pathogenesis of retinal degenerative diseases. Multiple studies
performed in the 21st century have observed that the secretion of proinflammatory cytokines and chemokines is integral in the pathogenesis of several
retinopathies including macular edema, age-related macular degeneration
(AMD), and diabetic retinopathy (90-93). Furthermore, during the examination of
postmortem donor eyes from patients with AMD, late-onset retinal degeneration,
and RP, large accumulations of activated microglia were detected within regions
of the outer nuclear layer (ONL) where photoreceptor degeneration was
occurring (83). These observations have prompted several researchers to once
again investigate the relationship between inflammation and disease progression
in RP.
The rd mouse is a widely used animal model of RP. Using this model,
Zeng et al. measured the production of mRNA and pro-inflammatory factors
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throughout the course of photoreceptor degeneration. It was observed that just
prior to the peak of cell death, there was a significant increase in the production
of MCP-1, MCP-3, MIP-1, MIP-1β, regulated on activation normal T cell
expressed and secreted (RANTES), and TNF-α. The chemokines caused the
activation and migration of microglial cells that released the TNF-α in the ONL
(94). Likewise, a study using porcine retinal explants treated with the
phosphodiesterase 6 (PDE6) inhibitor Zaprinast as a new model of RP, noticed
that an increased production of IL-6 and TNF-α was associated with the
photoreceptor cell death (61). In a study using S334ter-4 rats, which have a
mutation resulting in a truncated form of rhodopsin, a low dose of the synthetic
corticosteroid fluocinolone acetonide (FA) was shown to mitigate the
photoreceptor degeneration and preserve visual function. Intravitreous
administration of 0.2μg/day of FA, attenuated the ERG amplitude loss by 85%.
ONL thickness was preserved by 25.8% compared to the controls (six to eight
cell rows versus three to four rows at 12 weeks), and there was a seven to eight
times reduction in the presence of activated microglial cells in the photoreceptor
cell layer (70). Similar results were observed in CCL3-/-MERTK-/- mice. MERTK-/mice are a murine model of RP, and the CCL3-/-MERTK-/- mice are unable to
produce CCL3, also known as MIP-1α, which is necessary for the recruitment
and activation of polymorphonuclear leukocytes. The lack of CCL3 preserved the
ONL thickness, decreased the number of microglial and macrophage infiltrates,
and increased the BRB integrity by 50% compared to the dystrophic MERTK-/mice (71).
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In further support of inflammation playing a pivotal role in the
pathogenesis of RP, a set of studies performed by Yoshida et al. examined the
characteristics of the inflammatory response in both humans with RP and a
murine model (95, 96). In the clinical study, 371 RP patients and 165 control
patients were examined. A slit-lamp biomicroscope analysis was used to count
the number of cellular infiltrates present in the anterior vitreous cavity and
compare it to a retrospective analysis of the patient’s visual function. It was found
that while only two of the controls (1.21%) had five-to-nine cells per field in their
eyes, 37.3% of the RP patients had five-to-thirty cells per field, with the younger
patients commonly having the higher numbers. The RP patients with five or more
cells per field had significantly lower visual function scores compared to both the
control patients and RP patients with less or no cells in their anterior vitreous
cavity. Biopsies were also taken from the aqueous and vitreous humors of all
patients. It was observed that all RP patients had significantly elevated levels of
IL-8, MCP-1, and thymus and activation-regulated chemokine (TARC). In
addition, IL-6 was detected in 14 out of 16 RP samples while none was detected
in any control samples. In the vitreous humor, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8,
IL-10, IFN-γ, growth regulated oncogene-α, I-309, IFN-γ inducible protein (IP)-10,
MCP-1, MCP-2, and TARC were all significantly elevated in the RP patients
compared to the control patients (95). Taken together, these results suggest
chronic inflammation occurs in RP and is related to its pathogenesis.
To further investigate the role of inflammation, Yoshida et al. followed this
clinical study up with a laboratory study using the rd10 mouse model of RP (96).
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It was observed from real time polymerase chain reaction (PCR) of the RNA in
the total retinal tissue that MCP-1, IL-1β, RANTES, and TNF-α were significantly
upregulated by postnatal day (p)14, which is prior to the start of photoreceptor
cell loss, and maintained throughout the disease course. Immunohistochemistry
revealed that increased accumulations of Iba1+ activated microglial cells were
found in the subretinal space, ONL, and outer plexiform layer of rd10 retinas at
p14 and p21, while the retinas of wild type mice displayed none (96). Collectively,
the results of these studies demonstrate that the inflammatory response has an
integral role in the degeneration of photoreceptors in RP. Therefore, it can be
hypothesized that a treatment which is able to ameliorate the inflammation would
be beneficial to patients with RP.

Photobiomodulation
The use of specific wavelengths of light to induce biological changes in
cells is known as photobiomodulation (PBM) (97). It has been hypothesized that
far-red to near infrared (NIR) light (630-900nm) interacts with cytochromes in the
mitochondrial electron transport chain, triggering a cascade of intracellular events
culminating in improved cell survival. Cytochrome c oxidase (CcO) is the most
likely candidate to be this photoacceptor molecule, as the action spectrum for the
cellular effects of PBM corresponds to the absorption spectrum of CcO (98-101).
Nitric oxide (NO) competitively binds to CcO in mitochondria, replacing the
oxygen normally bound, and thereby inhibits mitochondrial respiration (98, 99,
102). When the NIR light reacts with CcO, it induces a conformational change
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which causes the NO to disassociate from the CcO resulting in an increased
production of adenosine triphosphate (ATP). The released NO has been
postulated to trigger the activation of gene transcription factors that regulate the
transcription of genes involved in many cellular functions, including apoptosis
and inflammation (98-103).
PBM has been shown to help promote healing, induce cell growth and
survival, and reduce inflammation for a variety of conditions. For example, a
study done by Muili et al. in 2012 treated C57BL/6 mice with experimental
autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis, with
670nm light and found that the disease was ameliorated. Evidence from
quantitative real-time PCR suggested that the 670nm light modulated the disease
by up-regulating the anti-inflammatory cytokines IL-10 and IL-4, while downregulating the pro-inflammatory cytokines IFN-γ and TNF-α (104). Similarly, in a
study performed by Assis et al., low-level laser therapy was used to treat muscle
cryolesions, and it was observed to both significantly reduce oxidative stress and
inflammation by modulating the gene expression of NF-κB and COX-2 (105).
Another example is a study that used 810nm light to treat rheumatoid arthritis.
The treatment not only showed an improvement in the arthritis, but a decrease in
the intracellular levels of TNF-α, IL-1β, and IL-8 (106). These studies are just a
few examples of different conditions in which PBM has been demonstrated to
ameliorate disease manifestations. It is likely that PBM may be successfully used
to ameliorate RP as well.
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Supporting this theory, several studies using PBM on retinopathies have
been performed with promising results. For instance, 670nm light has been used
to treat methanol-induced retinal toxicity in male Long-Evans rats. The methanol
intoxication results in retinal dysfunction and morphological changes in the
photoreceptors. Treatment with 670nm light (4.5 J/cm2) for 144 seconds at five,
24, and 50 hours after intoxication prevented the loss of retinal function and
histopathological changes associated with methanol intoxication (98). The
treatment of light-induced photoreceptor degeneration with 670nm light under
several different conditions (3 min/day at 5 J/cm2 for 2, 5, 7, or 10 days prior to
light-injury, or 3 min/day at 9 J/cm2 for 5 days either prior, during, or after lightinjury) has been shown to be neuroprotective. The treatments attenuated the
histological changes associated with the light damage, increased photoreceptor
cell survival and function, reduced the production of the stress-related molecule
glial fibrillary acidic protein (GFAP), modulated the production of neuroprotective
proteins, and decreased the inflammatory response (97, 107). In a study of
Retinopathy of Prematurity, which causes retina degeneration due to abnormal
vascular development in premature babies, 670nm light (3min/day, 9 J/cm2)
during hyperoxic exposure normalized retinal vascular development and
significantly prevented photoreceptor cell death in oxygen-induced retinopathy
mouse and rat models (108). In another PBM study performed by Kokkinopoulos
et al., 670nm light set at 40 mW/cm2 was used to treat age-related retinal
inflammation, and it was observed to significantly reduce inflammation, the
production of TNF-α, and the inflammatory markers complement component 3d
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and calcitonin (109). Similar results were observed by Begum et al. when using
670nm to treat a complement factor H knockout murine model of AMD. In this
study, 670nm light (6mins twice a day for 14 days, at 20 mW/cm2), used as part
of the environmental lighting produced a significant reduction in the expression of
complement component C3, the stress markers GFAP and vimentin, and
increased the expression of CcO (101). Moreover, when 830nm light
(3mins/day, 25 mW/cm2, 4.5J/cm2) was used to treat the P23H rat model of RP
during the peak time of photoreceptor loss, it was shown to attenuate the severity
of the disease. The animals treated with the 830nm light had 50% greater ERG
amplitudes for both rod and cone response, representing a significant
preservation of retinal function. In addition, histological assessments
demonstrated that the 830nm light protected against the loss of photoreceptor
cells in the retina (110). Collectively, these studies provide considerable
evidence to support the application of NIR PBM as a viable treatment option for
RP. PBM could be used to delay or prevent the loss photoreceptor cells by
modulating the inflammation response, reducing cell stress, and upregulating
neuroprotective factors. PBM may offer a non-invasive treatment option for
patients that is independent of inheritance pattern and can be effectively initiated
after the disease is diagnosed and photoreceptor degeneration has already
begun.
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II. Hypothesis and Specific Aims

RP is the most common cause of blindness in developed countries,
affecting approximately 1 in 4,000 people worldwide (1-5). Evidence suggests
chronic inflammation in the retina is a key factor in the pathogenesis of RP,
resulting in the degeneration of the photoreceptor cells (86-96). Currently, there
is no known treatment or preventive measure to halt the loss of photoreceptor
cells in RP. PBM offers a possible method to treat RP as it has been shown to
alleviate inflammation and preserve photoreceptor cell morphology and function
in other retinopathies (97, 98, 101, 107-109). Recent studies in the P23H rat
model of RP have shown that treatment with 830nm light significantly attenuated
photoreceptor degeneration and protected against the loss of visual function
(110). Considerable evidence supports the modulation of cytokine and
chemokine expression as a primary mechanism by which PBM mitigates
inflammation (104-106); thus it is likely that NIR light treatment attenuates
photoreceptor degeneration by up-regulating anti-inflammatory mediators and
down-regulating pro-inflammatory mediators. The overall goal of this study is to
determine the anti-inflammatory actions of 830nm light in the P23H rat model of
RP.

The hypothesis of this study is that treatment with 830nm light promotes
an anti-inflammatory environment in the retina. The specific aims listed below
were designed to test this hypothesis.
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1. Compare the concentrations of pro-inflammatory mediators in the
retinas of non-dystrophic SD rats with P23H rats and determine
the effect of 830nm light on pro-inflammatory mediators in the
retina of SD and P23H rats. The working hypothesis for this specific
aim is that there are differences in the pro-inflammatory mediators in
the retinas of P23H and SD rats and that treatment with the 830nm
light will reduce the retinal concentrations of pro-inflammatory
mediators.
2. Compare the concentrations of anti-inflammatory mediators in the
retinas of non-dystrophic SD rats with P23H rats and determine
the effect of 830nm light on anti-inflammatory mediators in the
retina of SD and P23H rats. The working hypothesis for this specific
aim is that there are differences in the anti-inflammatory mediators in
the retinas of P23H and SD rats and that treatment with the 830nm
light will increase the retinal concentrations of anti-inflammatory
mediators.
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CHAPTER 2: MATERIALS AND METHODS

I. Animal Model
Male and female Sprague-Dawley (SD) rats were obtained from Harlan
Sprague Dawley Inc. (Madison, WI). The albino SD rats were used as nondystrophic controls for retinal degeneration. Male and female homozygous P23H
transgenic rats were provided by the Retinal Degeneration Rat Model Resource
at the University of California, San Francisco. The homozygous P23H transgenic
rats were crossbred with the SD rats to produce heterozygous P23H transgenic
rats. The P23H transgenic rat is a widely accepted model RP as it bears a single
amino acid substitution at codon 23, which results in photoreceptor degeneration
similar to humans with RP caused by the autosomal dominant P23H mutation
(111). Heterozygous P23H rats are used instead of homozygous P23H rats
because they more accurately reflect the human genetic condition and disease
development, and the rate of retinal degeneration has been well defined for
heterozygous P23H rats (112).
All animals were bred and housed in the American Association for
Accreditation of Laboratory Animal Care approved facility in Lapham Hall at the
University of Wisconsin-Milwaukee. The animals were housed in an environment
which is humidity controlled and maintained at 21°C. The animals were provided
with food and water ad libitum and kept in a dim 12 hour light-and-dark cycle,
with an average of illuminance of 5-10 lux. All procedures were approved by the
Institutional Animal Care and Use Committee of the University of Wisconsin-
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Milwaukee and were conducted in compliance with the Association for Research
in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic
and Visual Research.

II. Near Infrared Light Treatment
Previous studies have demonstrated that using the wavelength of 830nm
was effective at attenuating the degeneration of photoreceptor cells (110). For
this reason, a wavelength of 830±10nm from a Gallium/Aluminum/Arsenide
(GaAIA) light-emitting diode (LED) array (QDI, Barneveld WI) was used for
treatment. The treatment was initiated on postnatal day (p) 17, and continued
daily until p27. Once per day, rats were placed in a clear polypropylene box with
the LED array placed on top. Each treatment consisted of 830±10nm irradiation
for 180 seconds at a light intensity of 25mW/cm2 resulting in a dose, or fluence,
of 4.5J/cm2. This dose of fluence of light has been documented to attenuate the
production of inflammatory cytokines in other disease models (98, 104).
Treatment controls were sham-treated by being restrained for 180 seconds in the
box with the array placed on top, but not exposed to the 830nm light.

III. Tissue Collection
The rats were euthanized at p30 by CO2 inhalation. Whole eyes and
retinas were collected from the rats immediately after euthanasia. Enucleated
eyes were punctured with a pointed scalpel at the corneal limbus and
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immediately immersed in 4% paraformaldehyde in 0.1 M phosphate-buffered
saline (PBS). The eyes were stored in the 4% paraformaldehyde overnight, then
transferred to a 4% sucrose solution in 0.1 M PBS and stored at 4°C. From the
non-enucleated eye, retinas were harvested. Eyes were held with a forceps at
the optic nerve while a 3-5mm incision was made in the corneal limbus. By
pulling the forceps from the optic nerve to the cornea, the retina was extracted
from the eye and immediately flash frozen in liquid nitrogen. The retinas were
stored at -80°C prior to analysis.

IV. Evaluation of Protein Concentration
Three or four retinas were pooled per sample. Each sample was
suspended in lysis buffer (10% protein inhibitor cocktail in PBS). The volume of
lysis buffer used was determined by multiplying the total retinal weight by 10 and
dividing by the number of retinas pooled. The tissue was then homogenized by
sonication. The samples were kept on ice during homogenization and sonicated
using a set of two 15 second pulses with a five second rest at 50% amplitude.
The samples were checked for uniform homogenization, then centrifuged at
13,000xg for five minutes at 4°C. The supernatant was collected and the pellet
discarded. The total protein concentration in each sample was then determined
using a Pierce™ Bicinchoninic Acid (BCA) Assay Kit from Thermo Scientific
according to the manufacturer’s instructions. Each sample was analyzed in a
1:10 and 1:100 dilution with PBS and compared to a standard curve ranging from
0 mg/mL to 2 mg/ml. The absorbance was measured for 570nm.
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V. Assessment of Cytokine and Chemokine Concentrations
Retinal samples were collected and homogenized by sonication. Samples
were stored at -80°C until the analysis was performed. The concentrations of
cytokine-induced neutrophil chemoattractant-3 (CINC-3), IL-1α, IL-6, IL-13, TNFα, IFN-γ, IL-4, vascular endothelial growth factor (VEGF), IL-10 and tissue
inhibitor of metalloproteinase-1 (TIMP-1) were analyzed using R&D Systems’
Magnetic Luminex Screening Assay kit. This assay is a multiplex bead based
sandwich enzyme-linked immunosorbent assay (ELISA) designed to quantitate
multiple cytokines and chemokines in serum, plasma, and tissue culture
supernatants. All procedures were performed according to the manufacturer’s
instructions. A Bio-Rad Bio-Plex analyzer (Dr. Coburn’s Lab, Medical College of
Wisconsin) was used to measure the concentration of each cytokine and
chemokine in pg/ml. Each sample was replicated, and analyzed compared to a
standard curve. The standard curve was constructed using a 3-fold dilution
series, with seven standards ranging from a 1:3 dilution to a 1:2,187 dilution.
Results were normalized to the total amount of protein in each sample.

VI. Statistics
The data was analyzed using a one-way analysis of variance (ANOVA)
followed by the Bonferroni post-hoc test. Alpha was set at 0.05 for all P-value
calculations to determine statistically significant differences between groups.
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CHAPTER 3: RESULTS
I. Rationale
Much is known about the phenotypic presentations of RP and the genetic
mutations that cause it. However, very little is known about the mechanisms
responsible for the pathology of RP. Although some investigators consider the
term “retinitis pigmentosa” to be a misnomer with respect to inflammation being
involved in pathogenesis, recent studies have provided evidence that chronic
inflammation in the retina is a key factor in initiating and propagating the
degeneration of photoreceptor cells in RP (86-96). NIR light has been
demonstrated to reduce inflammation and improve visual function and
photoreceptor cell survival in several other retinopathies (97, 98, 101, 107-109).
Moreover, previous experiments using the P23H rat model of RP have
demonstrated that treatment with 830nm light significantly attenuated the loss of
visual function and photoreceptor cell degeneration (110). Since PBM has been
shown to reduce inflammation by upregulating anti-inflammatory mediators and
downregulating pro-inflammatory mediators in various conditions (104-106), it is
suspected that the modulation of cytokines and chemokines produced in the
retina is a primary mechanism by which the 830nm light reduced the severity of
disease in the P23H rat. The purpose of this experiment was to assess the effect
of the 830nm light on the concentration of inflammatory mediators found in the
P23H rat retina. However, since inflammation in this model of RP has not been
previously characterized, any differences in the retinal concentrations of the
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inflammatory mediators in the P23H rat compared to the non-dystrophic
Sprague-Dawley rat were assessed first. Characterization of the inflammatory
cytokines and chemokines associated with disease in this model may lead to
possible potential therapeutic strategies for the treatment of RP.
The retinal concentrations of the following pro-inflammatory and antiinflammatory mediators were determined in this study because they have been
either implicated as major immune regulators in the rat eye or shown to be
significantly elevated in other models of RP:
1) Cytokine-Induced Neutrophil Chemoattractant (CINC)-3: Also
known as MIP-2, CINC-3 is a pro-inflammatory chemokine of the CXC
subfamily. Its human analog is known as growth regulated oncogene
(GRO) of the IL-8 family. As its name suggests, CINC-3 is the primary
neutrophil chemotactic factor found in rats, resulting in the infiltration of
neutrophils at sites of inflammation. It is primarily produced by monocytes
and macrophages, but has also been shown to be produced by epithelial
cells (113, 114). Moreover, the acute intraocular inflammation caused by
endotoxin induced uveitis in Lewis rats has been associated with
increased concentrations of CINC in the serum and aqueous humor (142).
2) Interleukin (IL)-1α: IL-1α is a pro-inflammatory cytokine produced by
macrophages and epithelial cells. It is known to cause T cell and
macrophage activation and has been shown to stimulate the production of
other pro-inflammatory factors, such as IL-1β and granulocytemacrophage colony stimulating factor in RPE cells (115, 116).
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3) IL-6: IL-6 is a pro-inflammatory cytokine produced by T cells,
macrophages, endothelial cells, and in the retina, Müller glial cells, and
RPE cells. It is known to have a wide range of effects on the inflammatory
response. In particular, it stimulates the proliferation and differentiation of
B and T cells, and triggers the production of acute phase reactants. The
production of IL-6 has been associated with the pathogenesis caused by
chronic inflammation in a variety of diseases, including RP (61, 95, 115,
117).
4) Tumor Necrosis Factor (TNF)-α: TNF-α is a pro-inflammatory cytokine
produced by macrophages, natural killer (NK) cells, and T cells. TNF-α
has multiple functions in the immune response, including stimulating the
proliferation, differentiation, and survival of immune cells, mediating
cytotoxic effects, and increasing vasodilation and vasopermeability. In the
retina, it has been shown to be produced primarily by glial cells and has
been associated with retinal degeneration in multiple retinopathies, such
as glaucoma, AMD, RP, and ischemic retinopathy (61, 91, 92, 94, 96, 118,
119).
5) Interferon (IFN)-γ: IFN-γ is a pro-inflammatory cytokine that is
produced by CD4+ TH1 cells, CD8+ T cells, and NK cells. The primary role
of IFN-γ is to activate macrophages, but it also increases MHC
expression, antigen processing, and Ig class switching, and suppresses
TH2 cells. IFN-γ is generally not present in the ocular tissues of healthy
eyes, and its presence has been associated with many ocular diseases. It

35
has been observed to cause intraocular cellular infiltration, microglia cell
proliferation, and photoreceptor cell death (115, 120).
6) Vascular Endothelial Growth Factor (VEGF): VEGF is a protein
produced by a variety of cells that stimulates vaculogenesis and
angiogenesis. In the retina, VEGF is primarily produced by RPE cells. The
production of VEGF is often induced by hypoxic conditions in order to
restore adequate oxygen supply to the cells. However, the overexpression
of VEGF has been shown to cause vascular leakage and neural retina
degeneration, implicating it in retinal diseases like AMD, diabetic
retinopathy, and RP (121, 122).
7) IL-4: IL-4 is an anti-inflammatory cytokine produced by CD4+ TH2 cells,
mast cells, and basophils. It is involved in regulating the T H2 immune
response by promoting the differentiation of TH2 cells instead of TH1 cells
from naïve T cells. IL-4 also drives the antibody response by helping to
initiate the proliferation and clonal expansion of B cells. A recent study
using murine models has demonstrated that IL-4 is primarily expressed in
the eye by RPE, choroid, and scleral cells. It was also shown that IL-4 had
the ability to suppress the proliferation of retinal progenitor cells and
promote their differentiation into rod photoreceptor cells in neonatal mice
(115, 123).
8) IL-13: IL-13 is an anti-inflammatory cytokine produced by TH2 cells.
Like IL-4, IL-13 promotes the growth and differentiation of B cells and
inhibits the differentiation of TH1 cells. Moreover, it also inhibits the
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production of pro-inflammatory mediators such as IL-1, IL-6, TNF-α, IL-8,
and MIP-1α from macrophages and monocytes. In addition, treatments
with IL-13 have been shown to reduce inflammatory in rat models of acute
ocular inflammation (115, 124).
9) IL-10: IL-10 is an anti-inflammatory cytokine produced by monocytes,
macrophages, and T cells. Together with IL-4, IL-10 promotes the TH2 cell
response instead of the TH1 cell response. In addition, IL-10 can inhibit the
expression of pro-inflammatory mediators from other cells. Studies have
shown that in the retina, photoreceptor cells are capable of producing IL10 in response to IL-27 produced by microglia cells. Furthermore,
endogenous and exogenous IL-10 has been observed to reduce
inflammation in uveitis (125, 126).
10) Tissue Inhibitor of Metalloproteinase (TIMP)-1: TIMP-1 is a
glycoprotein which inhibits the matrix metalloproteinase (MMP)-9. MMPs
are endopeptidases capable of degrading extracellular matrices. In the
retina, TIMP-1 is found in the interphotoreceptor matrix, which is between
the photoreceptors and RPE, and it is suggested that RPE cells may be
responsible for the secretion of TIMP-1. In multiple retinal degenerative
diseases, TIMP-1 has been observed to be significantly increased.
Furthermore, intravitreal injections of TIMP-1 in a S334-ter-line-3 rat
model of RP demonstrated that TIMP-1 is capable of helping to restore the
homogeneity of photoreceptors in the retina by preventing the formation of
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photoreceptor rings around areas of cell death and causing the remaining
photoreceptors to be evenly spaced throughout the retina. (127, 128).

II. Compare the concentrations of pro-inflammatory mediators in
the retinas of non-dystrophic SD rats with P23H rats and
determine the effect of 830nm light on pro-inflammatory
mediators in the retina of SD and P23H rats.
Concentrations of Pro-Inflammatory Mediators in the P23H Rat Retina
The retinal concentrations of six pro-inflammatory mediators were
measured: CINC-3, IL-1α, IL-6, TNF-α, IFN-γ, and VEGF. No statistically
significant differences were observed between the P23H retina and the SD
retina. However, we saw trends that were opposite of what we anticipated.
Retinal concentrations of five of the six pro-inflammatory mediators were lower in
the P23H rat than the SD rat. The average IL-6 retinal concentration was 813
pg/mL/mg retinal protein in the SD rat, while it was 683 pg/mL/mg retinal proteins
in the P23H rat (16% less) (Figure 1). Likewise, TNF-α was found at an average
concentration of 96 pg/mL/mg retinal protein in the SD rat and 79 pg/mL/mg
retinal protein in the P23H rat (18% less) (Figure 2). Somewhat greater
differences were observed in the mean retinal concentrations of IFN-γ, VEGF,
and CINC-3. Retinal concentrations of IFN-γ and VEGF were 29% and 36%
lower, respectively, in the P23H retina compared to the SD retina (268 pg/mL/mg
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Figure 1. Concentration of IL-6 found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. Error bars indicate SEM. No statistically significant
differences (P<0.05).

retinal protein vs. 192 pg/mL/mg and 90 pg/mL/mg vs 137 pg/mL/mg) (Figures 3
and 4). Of all the pro-inflammatory mediators, CINC-3 showed the greatest
difference. The mean concentration of CINC-3 in the P23H retinas was 52%
lower than that measured in the SD retina (26 pg/mL/mg retinal protein vs. 54
pg/mL/mg) (Figure 5). IL-1α was the only cytokine of the six pro-inflammatory
mediators measured to have a higher mean retinal concentration in the P23H
rats. However, the average IL-1α concentration was still nearly identical in the
retinas of the two animals, as the P23H rat had only a 5% increase compared to
the SD retinal concentration (120 vs. 115 pg/mL/mg retinal protein) (Figure 6).
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Figure 2. Concentration of TNF-α found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. Error bars indicate SEM. No statistically significant
differences (P<0.05).

Effects of 830nm Light on Retinal Concentrations of Pro-Inflammatory Mediators
No significant differences were observed in the retinal concentrations of
the pro-inflammatory mediators between the sham treated and 830nm light
treated rats. The standard error of the mean was large for each mediator
measured, due to the small sample sizes used. The changes observed due to
the 830nm light treatment were very minor, as the greatest reduction was only
13% with TNF-α (Figure 2). IL-6 was reduced by 11%, and VEGF was 4% less in
the light treated P23H rats compared to the sham treated (Figures 1 and 4). IL-1α
displayed no differences with the light treatment, as the average retinal
concentration remained at 121 pg/mL/mg retinal protein (Figure 6). Similarly, the
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Figure 3. Concentration of IFN-γ found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. Error bars indicate SEM. No statistically significant
differences (P<0.05).

average retinal concentration of IFN-γ after the 830nm light treatment was only
2% greater than the sham treated P23H rats (Figure 3). CINC-3 was the only
pro-inflammatory mediator to be increased by more than a marginal amount with
the 830nm light. Its average retinal concentration was 19% greater in the light
treated P23H rats compared to the sham treated P23H rats (Figure 5).
In contrast to the P23H rats, the retinal concentrations of all six proinflammatory mediators were increased in the SD rats treated with the 830nm
light compared to the sham treated SD rats. Still, none of these differences were
statistically significant. However, while most of the changes observed between
the P23H rats were marginal, the differences between the light treated SD rats
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Figure 4. Concentration of VEGF found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. Error bars indicate SEM. No statistically significant
differences (P<0.05).

and sham treated rats were generally larger. The increases ranged between 11%
and 42% for IFN-γ and TNF-α, respectively (Figures 3 and 2).
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Figure 5. Concentration of CINC-3 found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. Error bars indicate SEM. No statistically significant
differences (P<0.05).

Figure 6. Concentration of IL-1α found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. Error bars indicate SEM. No statistically significant
differences (P<0.05).
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III. Compare the concentrations of anti-inflammatory mediators
in the retinas of non-dystrophic SD rats with P23H rats and
determine the effect of 830nm light on anti-inflammatory
mediators in the retina of SD and P23H rats.
Concentrations of Anti-Inflammatory Mediators in the P23H Rat Retina
Four anti-inflammatory mediators were measured with the Magnetic
Luminex Screening assay: IL-13, IL-4, IL-10 and TIMP-1. There was no
difference between the average P23H and SD retinal concentrations of IL-13, as
both contained approximately 39 pg/mL/mg retinal protein (Figure 7). There was
20% more IL-4 present in the P23H retina than the SD retina (26 pg/mL/mg vs.
21 pg/mL/mg) respectively, yet this was not statistically significant (Figure 8).

Figure 7. Concentration of IL-13 found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. Error bars indicate SEM. No statistically significant
differences (P<0.05).
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Figure 8. Concentration of IL-4 found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. Error bars indicate SEM. No statistically significant
differences (P<0.05).

Likewise, there was no statistically significant difference between the P23H and
SD retinal concentrations of IL-10. However, the average P23H retinal
concentration of 21.44 pg/mL/mg retinal protein was 33% less than the average
retinal concentration of 32 pg/mL/mg retinal protein observed in the SD retina
(Figure 9). Conversely, the retinal concentrations of TIMP-1 was significantly
greater in the P23H rat compared to the SD rat (P=0.008). The average level of
TIMP-1 observed in the P23H retina was 96% greater than what was observed in
the SD retina, at 24,357 pg/mL/mg retinal protein compared to 9,234 pg/mL/mg
retinal protein (Figure 10).
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Figure 9. Concentration of IL-10 found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. * denotes a statistically significant difference
(P<0.05). Error bars indicate SEM.

Effects of 830nm Light on Retinal Concentrations of Anti-Inflammatory Mediators
No significant differences were observed in the retinal concentrations of
the anti-inflammatory mediators between the sham treated and 830nm light
treated rats. The trends that we observed in the P23H rats indicated that the
830nm light treatment decreased the retinal concentration of all four of the antiinflammatory mediators. IL-4 displayed the greatest change, with a 24%
reduction in the light treated rats compared to the sham treated rats (Figure 8).
IL-13 was observed to have a 19% reduction, and IL-10 was reduced by 12%
(Figures 7 and 9). TIMP-1 had the least alteration of its retinal concentration
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Figure 10. Concentration of TIMP-1 found in retinal samples of sham treated
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5),
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples
were obtained at p30. * denotes a statistically significant difference (P<0.05).
Error bars indicate SEM.

caused by the 830nm light treatment, being reduced by only 4% compared to the
sham treated P23H rats (Figure 10).
The opposite trends were observed in the SD rats. All of the antiinflammatory mediators were found to be elevated in the light treated SD rats
when compared to the sham treated SD rats. The most notable difference of this
group was in the average retinal concentration of TIMP-1, which was observed to
be 9,234 pg/mL/mg retinal proteins in the sham treated SD rats and 16,561
pg/mL/mg retinal protein in the light treated SD rats, a 45% increase (Figure 10).
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Furthermore, the retinal concentration of IL-10 was found to be
significantly greater in the SD light treated rats compared to the P23H light
treated rats (P=0.00028) (Figure 9).
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CHAPTER 4: DISCUSSION
The secretion of inflammatory cytokines and chemokines has been
associated with the pathogenesis of multiple retinopathies, including AMD,
diabetic retinopathy, and late-onset retinal degeneration (83, 90-93). Following
these observations, the concept that inflammation was involved in RP was
renewed. PBM, which is the use of light to induce a biological change in cells,
has been demonstrated to reduce inflammation for a variety of conditions (98109). Recent experiments have shown that 830nm PBM is capable of
significantly alleviating RP in the P23H transgenic rat model. The 830nm PBM
preserved rod and cone ERG responses and prevented the loss of photoreceptor
cells (110). However, the mechanism by which the 830nm light attenuated
disease is unknown. Since the reduction of inflammation by up-regulating antiinflammatory mediators and down-regulating pro-inflammatory mediators has
been reported in a variety disease states following PBM (104-106), we
hypothesized that the modulation of cytokines and chemokines may be a primary
mechanism by which the 830nm PBM ameliorated the degeneration of the
photoreceptor cells in the P23H rat. However, the inflammatory profile of the
retina of the P23H rat has never been characterized. For this reason, the
following specific aims were designed to assess the association of cytokines and
chemokines with retinal degeneration in the P23H rat, and determine the effect of
830nm light on the inflammatory mediators in the retina of the P23H rat.
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1. Compare the concentrations of pro-inflammatory mediators in the
retinas of non-dystrophic SD rats with P23H rats and determine the
effect of 830nm light on pro-inflammatory mediators in the retina of
SD and P23H rats. The working hypothesis for this specific aim is that
there are differences in the pro-inflammatory mediators in the retinas of
P23H and SD rats and that treatment with the 830nm light will reduce the
retinal concentrations of pro-inflammatory mediators.

2. Compare the concentrations of anti-inflammatory mediators in the
retinas of non-dystrophic SD rats with P23H rats and determine the
effect of 830nm light on anti-inflammatory mediators in the retina of
SD and P23H rats. The working hypothesis for this specific aim is that
there are differences in the anti-inflammatory mediators in the retinas of
P23H and SD rats and that treatment with the 830nm light will increase
the retinal concentrations of anti-inflammatory mediators.

I. Compare the concentrations of pro-inflammatory mediators in
the retinas of non-dystrophic SD rats with P23H rats and
determine the effect of 830nm light on pro-inflammatory
mediators in the retina of SD and P23H rats.
Retinas were harvested from the dystrophic P23H rats and the nondystrophic SD rats at postnatal day (p)30 to compare the retinal concentrations of
the selected inflammatory mediators. Interestingly, pro-inflammatory cytokine and
chemokine concentrations did not differ between P23H and SD retinas.
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Unexpectedly, the concentrations of most of the pro-inflammatory mediators
appeared to be slightly lower in the retinas of P23H rats than those of the SD
rats. Due to the large variability in individual values and the small sample size,
statistical significance was not obtained. The concentrations of two proinflammatory mediators, CINC-3 and VEGF, appeared to be substantially lower
in the retinal tissue from P23H rats compared to SD rats. The retinal
concentration of CINC-3 in the P23H retina was approximately half of that
measured in the SD retina. As cellular infiltration of the retina has been one of
the most constant observations of previous clinical and laboratory studies of
inflammation in RP (70, 71, 83, 95, 96), it was surprising to find that the primary
neutrophil chemotactic factor of rats was not elevated. However, while IL-8 and
GRO, which are in the same family as CINC-3, have been shown to be
significantly elevated in the aqueous and vitreous humors of human patients with
RP (95), neither CINC-3 nor MIP-2 have been observed in rat or murine models
of RP. Therefore, it is possible that CINC-3 is not involved in the recruitment of
microglia or other immune cells infiltrating the retina in this model of RP. Similarly
to CINC-3, the concentrations of VEGF in the P23H retinas were one-third less
than that measured in the SD retinas. This was also contrary to what we
anticipated, as elevated levels of VEGF have been implicated in the
pathogenesis of retinal diseases, including AMD, diabetic retinopathy, and RP.
For example, the overexpression of VEGF has been demonstrated to cause
vascular leakage and retinal degeneration in Royal College of Surgeon (RCS)
rats (122). Also, the intravitreal injection of bevacizumab, which is an anti-
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angiogenesis drug that suppresses VEGF, into RP patients has been shown to
preserve the central macular thickness (121). These results suggest that
increased concentrations of VEGF may be associated with retinal degeneration;
however, one of the clinical manifestations of RP is the attenuation of retinal
arterioles, which becomes progressively more severe as the disease develops
(8, 11). Since the primary function of VEGF is angiogenesis (121, 122), the
continued attenuation of the retinal arterioles may suggest that while VEGF
expression may be involved in the initiation of disease, its expression decreases
as the disease progresses. In this experiment, retinal tissues were harvested at
p30, after the disease has significantly developed (135). For this reason, the
expression of VEGF may have decreased in the dystrophic P23H rats compared
to the non-dystrophic SD rats.
In order to assess the effect of the 830nm light on the pro-inflammatory
mediators, dystrophic P23H rats and non-dystrophic SD rats were either treated
with 830nm light or sham treated for 10 days, starting at p17. Retinal tissue was
harvested from the light treated and sham treated rats at p30, and cytokine and
chemokine concentrations were measured and compared. No significant
differences in the retinal concentrations were detected between sham treated
and 830nm light treated rats. Yet, there was a slight reduction in the average
retinal concentration of three of the six pro-inflammatory mediators measured.
While these differences were minor, because of the small sample size and the
timing of the retinal harvest these lowered concentrations may suggest an antiinflammatory influence of the 830nm light.
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II. Compare the concentrations of anti-inflammatory mediators in
the retinas of non-dystrophic SD rats with P23H rats and
determine the effect of 830nm light on anti-inflammatory
mediators in the retina of SD and P23H rats.
The only anti-inflammatory mediator that was observed to be
significantly different between the P23H rat and the SD rat was TIMP-1. The
retinal concentration of TIMP-1 in the P23H retina was nearly double that
measured in the SD retina. This finding partially supports our hypothesis, in that
the imbalance of TIMPs and the MMPs they inhibit have been implicated in the
pathogenesis of central nervous system inflammatory diseases and retinal
degeneration (127, 128, 129). TIMP-1 has additional roles in beyond inhibiting
MMPs, such as activating growth factors, inhibiting angiogenesis, promoting cell
proliferation, and upregulating anti-apoptotic processes (130). Furthermore, the
secretion of MMPs and TIMPs by astrocytes and microglial cells has been shown
to be induced by IL-1β, TNF-α, and lipopolysaccharides during states of
inflammation (131). MMPs are often disproportionately elevated compared to the
TIMPs, overwhelming the inhibition; however, the elevated expression of TIMP-1
has been suggested as a biomarker for the severity of diseases associated with
chronic inflammation. For example, in studies of inflammatory bowel disease and
liver fibrosis from chronic hepatitis B, serum levels of TIMP-1 have been
demonstrated to be significantly correlated with the degree of inflammation
observed in patients (136, 137). Additionally, a study examining the expression
of MMPs and TIMPs in experimental autoimmune encephalomyelitis (EAE) found
that the expression of TIMP-1 was restricted to activated astrocytes surrounding
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inflammatory lesions (129). Therefore, the significant elevation of TIMP-1 in the
retinas of the P23H rats may suggest an inflammatory retinal environment.
No differences in concentrations of the anti-inflammatory cytokines IL-4
and IL-13 were observed between the dystrophic P23H retinas and the nondystrophic SD retinas. The retinal concentration of IL-10 in the P23H rat was
one-third less than what was measured in the retina of the SD rat. This difference
was not statistically significant; however, due to the small sample sizes and large
variability, it may still indicate a potential difference between the P23H and SD
retinas. IL-10 is a potent anti-inflammatory cytokine capable of suppressing the
expression of multiple pro-inflammatory mediators for macrophages and T H1
cells, such as IL-1β, IL-6, IL-8, TNF-α, and IFN-γ (115, 126, 138). Consequently,
IL-10 deficiency has been linked to intensified and prolonged inflammation
responses in multiple disease states (125, 139, 140, 141). Thus, if the lower
retinal concentrations of IL-10 observed in the P23H retinas compared to the SD
retinas can be confirmed in future studies with larger sample it sizes, it would
support our hypothesis by suggesting pro-inflammatory environment in retina of
the P23H rat.
It was expected that the 830nm light treatment would increase the retinal
concentrations of the anti-inflammatory mediators, but in this experiment it was
observed that the concentrations of all four anti-inflammatory mediators were
decreased. However, these reductions were not statistically significant.
Additionally, the standard error of the mean was extremely large for each
mediator measured. Taken together, these results indicate that the 830nm PBM
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had no effect on the retinal concentrations of the anti-inflammatory mediators.
Interestingly, a significant difference was observed between the light treated
P23H rats and light treated SD rats in the retinal concentration of IL-10. This
significant difference may support the potential difference between the untreated
P23H and SD rats’ IL-10 retinal concentrations discussed above. The light
treated sample sizes contained one more rat than the untreated sample sizes,
this slight increase may have allowed the significant difference to be detected.

III. Discussion
Studies have shown that the peak photoreceptor degeneration in the
P23H rat occurs at approximately postnatal day 20 (112, 135). Moreover, the
inflammatory response has been shown to precede photoreceptor cell loss (94,
96). Thus, it is possible that we were unable to detect differences in the retinal
concentrations of the pro-inflammatory and anti-inflammatory mediators between
the P23H rats and the SD rats in our study because we harvested retinal tissue
after the peak of inflammation in this model. In the heterozygous P23H rat, the
majority of photoreceptors are lost by p60, with the peak of photoreceptor
degeneration occurring at approximately p20. At p30 the photoreceptors are still
degenerating, but at a significantly slower rate than at the p20 peak (112, 135). If
inflammation is a factor in driving the degeneration of photoreceptors in the P23H
transgenic rat model of RP, then the production of inflammatory mediators is
likely to be predominately occurring prior to, or during, the peak of photoreceptor
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cell death. By p30, the immune system may have adapted the chronic
inflammation and returned the majority of cytokine and chemokine production to
homeostasis in the retina.
This reasoning that the timing of our retinal harvest was too late to
observe elevated concentrations of our chosen inflammatory mediators is
supported by the evidence provided in the studies performed by Zeng et al. and
Yoshida et al., which observed the production of pro-inflammatory factors during
the disease course of murine models of RP. Zeng et al. measured the apoptosis
of photoreceptor cells in the rd mouse at p8, 10, 12, 14, 16, and 18 and found
that the photoreceptor cell death began at p10 and peaked at p16. Additionally,
Zeng et al. demonstrated that the production of MCP-1, MCP-3, MIP-1, MIP-1β,
RANTES, and TNF-α was significantly increased by p8 and peaked at p12. This
corresponded with the activation of microglial cells, which started at p10 and
peaked by p14 (94). Likewise, using the rd10 mouse model of RP, Yoshida et al.
demonstrated that the retina expression of MCP-1, IL-1β, RANTES, and TNF-α
was significantly upregulated by p14 prior to the start of photoreceptor cell loss.
This upregulated expression was maintained throughout the course of the
disease; however, the expression of MCP-1 and TNF-α was halved by p17 and
continued to decrease through p21 and p28. Similarly, the IL-1β expression was
nearly 10 times less by p17. The retinal expression of RANTES was the only
factor measured to increase over time from p17 to p28 (96). Since Zeng et al.
and Yoshida et al. show that the pro-inflammatory mediators were produced
mainly before photoreceptor cell death, these results suggest that a better
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strategy to assess the role of inflammation in the retinal degeneration of the
P23H rat would involve a time course. Additional studies should be performed to
establish the time course of cytokine and chemokine expression during the onset
and development of disease in the P23H rat. Since the photoreceptor cell loss
peaks at p20 in this model of RP, it is suggested the expression should be
measured beginning at p5 and again at p10, p15, p20, p25, and p30.
Achieving measurable concentrations of each inflammatory mediator was
another difficulty with this experiment that may have masked the effects of the
830nm light. Due to the small size of the rat eye, retinas needed to be pooled in
groups of three or four to obtain sufficient concentrations for the screening assay
used. This greatly limited the sample size of each group, and may have limited
the assay’s ability to detect statistically significant differences. In future
experiments, quantitative real-time PCR may be used to determine the level of
mRNA for each inflammatory mediator. This technique has been used to
measure the expression of cytokines and chemokines in the retinas of murine
models of RP (94, 96), and may be a more accurate method when dealing with
small tissue samples. Also, it is possible that the cytokines and chemokines
primarily associated with the retinal inflammation in the P23H rat were not among
the 10 factors tested in this experiment. The pro-inflammatory factors MCP-1, IL1β, MIP-1, and RANTES are additional potential targets to investigate, as these
factors have been shown to be significantly elevated in several murine models of
RP as well as patients with RP (71, 94-96).
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The finding that the light treatment had no significant effects on the retinal
concentrations of the cytokines and chemokines measured is unsurprising due to
the minimal signs of inflammation observed at the time examined. If inflammation
is not a significant factor in the pathogenesis of the disease, then there is no
response for the NIR light treatment to down-regulate. Furthermore, the timing of
the retinal harvest may have been inadequate to accurately measure the effect of
the 830nm light treatment. As discussed earlier, the majority of the production of
pro-inflammatory factors is likely occurring prior to or during the peak of
photoreceptor cell loss (94-96). In addition, as demonstrated by Yoshida et al. in
the rd10 mouse, the expression of inflammatory factors can change rapidly. In
the three day period between the initial and next sequential measurement, the
retinal expression of MCP-1, TNF-α, and IL-1β was reduced by half or more (96).
Therefore, any significant modulation of the inflammatory response due to the
830nm light treatment is likely occurring in the first half of the 10 day treatment,
when the rate of photoreceptor degeneration is highest (112). In order to verify
the effect of 830nm PBM, a time course study examining the retinal
concentrations prior, during, and immediately after the light treatment is
suggested.
There is also the possibility that the 830nm light treatment had no effect
on the inflammatory response of the P23H rat. In this experiment, the 830nm
light was used in order to replicate the methods used in the previous study using
the P23H rat model of RP. However, this wavelength may not be the most
effective treatment. While the NIR wavelengths between 630-900nm have been
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shown to be reactive with cytochrome c oxidase (CcO) and able to modify
cellular functions in order to promote cell growth and survival, the efficacy of
each wavelength is different. During the comparison of the absorption spectrum
of CcO and its activity after exposure to various far-read and NIR wavelengths, it
was demonstrated that wavelengths of 670nm and 830nm both corresponded
with the peaks of absorbance and activation (132). For this reason, these two
wavelengths have commonly been used for the treatment of various conditions.
However, the most effective wavelength and treatment parameters are
dependent on the condition, the affected tissue type, and location being treated
(102, 133, 134).
A study performed by Giacci et al. examined the efficacy of 670nm and
830nm light treatments in four different rat models of central nervous system
injury, which included a light-induced retinal degeneration model. It was found
that the efficacy of each wavelength varied by the injury type. In the case of the
light induced retinal degeneration, it was demonstrated that a five day pretreatment with 670nm light (3mins/day at 3.4J/cm 2) was able to significantly
reduce the amount photoreceptor cell death after injury, but a five day pretreatment with 830nm light (3min/day at 2.7J/cm2) was not (134). Additionally,
when a reduction of inflammation was observed in other studies using NIR light
to treat retinal degeneration, 670nm light was used instead 830nm light (97, 101,
107, 109). Taken together, this suggests that using 670nm light with the P23H rat
model of RP may provide a greater effect on the retina’s inflammation response
than the 830nm light.
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In summary, the working hypothesis of aim 1 was that there are
differences in the pro-inflammatory mediators in the retinas of P23H and SD rats
and that treatment with the 830nm light will reduce the retinal concentrations of
pro-inflammatory mediators. The data provided by this experiment did not
support this hypothesis, as no significant differences in retinal concentrations of
the pro-inflammatory mediators were observed between P23H and SD rats; nor
were significant differences observed between the 830nm light treated rats and
sham treated rats. The working hypothesis of aim 2 was that there are
differences in the anti-inflammatory mediators in the retinas of P23H and SD rats
and that treatment with the 830nm light will increase the retinal concentrations of
anti-inflammatory mediators. The data provided by this experiment partially
support this hypothesis, as a significant difference between the P23H rat and SD
rat in the retinal concentrations of TIMP-1 was observed, which may suggest an
inflammatory environment in the retina of the P23H rat. In addition, the retinal
concentration of IL-10 was lower in the P23H retinas than the SD retinas,
signifying a potential inability to regulate an exacerbated or prolonged
inflammatory response occurring in the retina. While this difference was not
statistically significant between the untreated P23H and SD rats, it was
significantly different between the light treated P23H and SD rats. We suspect
that if the sample size was increased, a significant difference would be observed.
However, no significant differences were observed in the anti-inflammatory
mediators between the 830nm light treated rats and the sham treated rats.
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After comparing the experimental design of this study with the design of
previous studies examining the production of inflammatory mediators in animal
models of RP, we conclude that the timing of the retinal harvest may have been
too late to evaluate the expression of inflammatory cytokines and chemokines in
the retina of the P23H rat and to observe the effects of the light treatment.
Additional experiments will be needed to establish a time course for the
expression of cytokines and chemokines through the disease course of the P23H
rat, beginning prior to the start of photoreceptor cell death. Once a time course is
established, further experiments with the 830nm light are needed to measure the
retinal concentrations of the inflammatory mediators prior to treatment, during
treatment, and immediately after treatment in order to verify the effect of 830nm
light on the production of inflammatory mediators in the retina of the P23H rat.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
RP is the most common cause of blindness in developed countries,
affecting 1 in 4,000 people (1-5). RP was first described in 1857 (85). Since then,
the clinical manifestations of the disease have been well characterized and over
half the genetic mutations responsible for RP have been identified (1). Despite
this, little is known about the mechanisms of the disease. Despite considerable
efforts, there are currently no effective treatment or preventative measures for
RP. Photobiomodulation using light in the far-red to NIR range of the spectrum
has been shown to attenuate inflammation, improve retinal function, and prevent
photoreceptor cell death in several other retinopathies (97, 98, 101, 107-109).
Recent investigations using the P23H rat model of RP provide evidence that both
670nm and 830nm PBM protect against photoreceptor cell death (110). Taken
together, these studies provide considerable evidence to support the application
of NIR light as a potential treatment for RP. However, PBM must achieve FDA
approval before it will be used to treat patients. In order to gain this approval, the
mechanism by which the NIR light functions to ameliorate disease it must be
identified. The objective of this thesis to contribute to this knowledge by
characterizing the role of retinal inflammation in the pathogenesis of RP and
determining if reducing inflammation is a mechanism by which PBM attenuates
retinal degeneration.
These experiments tested the hypothesis that 830nm light promotes an
anti-inflammatory environment in the retina. Overall, the hypothesis of this study
was only partially supported, as no effects of the 830nm PBM were observed, but
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differences seen in the cytokine and chemokine retinal concentrations suggested
inflammation is occurring in the P23H rat retina. These results are novel as this is
the first study to investigate inflammation in the P23H rat, which is a widely used
model of RP. Moreover, the results of this study aid in characterizing the role of
inflammation in RP, as not many studies have examined the role of inflammation
in the pathogenesis of RP despite its implication in initiation and propagation of
other retinal degenerative diseases (90-93). Establishing a role of inflammation in
RP allows for the development of potential treatment options for patients by
identifying a mechanism that can be manipulated to delay or halt the
degeneration of photoreceptor cells. Supporting this idea of targeting
inflammation for the treatment of RP, intravitreal injections of fluocinolone
acetonide (FA) in several other rat models of retinal degeneration have been able
to reduce microglia cell activation and migration, as well as preserve visual
function and prevent photoreceptor cell death (70). Therefore, additional
experiments comparing the effects of intravitreal FA injections and NIR light
treatments in the P23H rat should be performed. In addition to providing
evidence that could demonstrate a causal role for inflammation in the
pathogenesis of RP, by comparing the results of the NIR light treatment and the
FA treatments, the modulation of inflammation may be verified as a mechanism
by which NIR light attenuates photoreceptor degeneration in the P23H rat.
In order to fully characterize the inflammatory response in the retina of the
P23H rat model of RP and elucidate the protective mechanisms of PBM, future
experiments should be designed to evaluate the complete inflammatory pathway.
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For example, the presence of cellular infiltrates and the migration of microglia
cells from the inner nuclear layer to the outer nuclear layer has been associated
with the photoreceptor degeneration observed in both humans and animals with
RP (70, 71, 83, 89, 94-96). Therefore, a histological analysis of the activation and
infiltration of immune cells in the retina of the P23H rat would not only assess the
presence of an inflammatory response, but provide information about the type of
immune cells involved. Identifying the primary immune cells infiltrating the ocular
tissues of the P23H rat could help determine which cytokines and chemokines
are likely being expressed. This information could then be used to optimize the
measurement of inflammatory changes caused by PBM. Alternatively, measuring
the gene expression of NF-κB or other inflammatory transcription factors may be
used to assess the regulation of inflammation in the retina (115), as NIR light
treatments have been demonstrated to modulate the expression of NF-κB in
other conditions (105).
Understanding the mechanisms of PBM is essential for achieving FDA
approval, allowing it to be used for the treatment of RP patients. PBM may offer a
non-invasive, easy to use treatment option with minimal side effects. Unlike gene
therapy and steroid treatments, PBM does not use injections, eliminating the risk
of infections or injury. The devices used to administer NIR light treatments can be
small and preset, making them usable by patients at home. PBM also has the
potential to be effective for a wide range of RP patients, as it is not targeted to
specific mutations. Furthermore, an obstacle of other treatment methods has
been the inability to halt photoreceptor cell death after degeneration has begun
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(40). PBM has been shown to be able to preserve photoreceptor cells when
treatment was initiated at the peak of photoreceptor cell death. This makes PBM
an ideal treatment option since patients may have significant photoreceptor cell
loss before RP is diagnosed (1, 8, 27, 28). The insights obtained from this
research advance our knowledge about the mechanisms behind RP and PBM,
bringing an effective treatment one step closer to development for RP patients.
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